Oral Treatments in the Patients with Metastatic Breast Cancer - A Case Series

Mehrdad Payandeh¹, Noorodin Karami², Afshin Karami^3, , Mehrnoush Aeinfar¹, Fatemeh Feizi³ and Amir Yami³

¹Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran

²Department of Genetics, Shahid Sadoughi University of Medical Science, Yazd, Iran

³Department of Hematology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Cite this paper:
Mehrdad Payandeh, Noorodin Karami, Afshin Karami, Mehrnoush Aeinfar, Fatemeh Feizi and Amir Yami. Oral Treatments in the Patients with Metastatic Breast Cancer - A Case Series. American Journal of Cancer Prevention. 2018; 6(2):29-31. doi: 10.12691/ajcp-6-2-3

Abstract

Breast cancer is one of the most common malignant diagnostic tumors among women and is considered as the second leading cause of mortality in them. Numerous approaches could be recruited for breast cancer management such as surgery, radiation therapy, endocrine, and chemotherapy. In past years, oncologists have prescribed intravenous anticancer drugs for many patients, but nowadays the issue of treatment has changed with the increasing use of oral anticancer drugs. Previous studies have shown that most patients prefer to take oral anticancer drugs and their main reason for this choice is the accessibility of home-based treatment. The objective of this issue was to evaluate the effects of oral therapy regimens such as palbociclib (Ibrance) in combination with aromatase inhibitors in patients with metastatic breast cancer. Our new remedies in the oral therapy field in 2 patients lead to control the progress of malignancy.

Keywords:
breast cancer oral therapy palbociclib ibrance

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Anjum F, Razvi N, Masood MA (2017) Breast Cancer Therapy: A Mini Review. MOJ Drug Des Develop Ther 1(2): 00006.
[2]	Goldhirsch A2, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, Panel members. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of oncology. 2011 Jun 27; 22(8): 1736-47.
[3]	Weigelt B, Peterse JL, Van't Veer LJ. Breast cancer metastasis: markers and models. Nature reviews. Cancer. 2005 Aug 1; 5(8): 591.
[4]	Lukaszewicz K, Wtorek J, Bujnowski A, Skokowski J. Monitoring of breast tissue thermo-ablation by means of impedance measurements. In Journal of Physics: Conference Series 2010 (Vol. 224, No. 1, p. 012136). IOP Publishing.
[5]	Yamamoto-Ibusuki M, Arnedos M, André F. Targeted therapies for ER+/HER2-metastatic breast cancer. BMC medicine. 2015 Jun 9; 13(1): 137.
[6]	Robb GL, Hortobagyi GN. Advanced therapy of breast disease. PMPH-USA; 2004.
[7]	Bernards R, Weinberg RA. Metastasis genes: a progression puzzle. Nature. 2002; 418(6900): 823.
[8]	Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA: A Cancer Journal for Clinicians. 2009; 59(1): 56-66.
[9]	Yabroff KR, Warren JL, Knopf K, Davis WW, Brown ML. Estimating patient time costs associated with colorectal cancer care. Medical care. 2005 Jul 1; 43(7): 640-8.
[10]	Banna GL, Collovà E, Gebbia V, Lipari H, Giuffrida P, Cavallaro S, Condorelli R, Buscarino C, Tralongo P, Ferraù F. Anticancer oral therapy: emerging related issues. Cancer treatment reviews. 2010 Dec 31; 36(8):595-605.
[11]	Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011 Mar 1; 61(2): 69-90.
[12]	Li XP, Meng ZQ, Guo WJ, Li J. Treatment for liver metastases from breast cancer: results and prognostic factors. World journal of gastroenterology: WJG. 2005 Jun 28; 11(24): 3782.
[13]	Ehab M, Elbaz M. Profile of palbociclib in the treatment of metastatic breast cancer. Breast Cancer: Targets and Therapy. 2016; 8: 83.
[14]	Perez EA. Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order. Drug Resistance Updates. 2016 Jan 31; 24: 13-22.
[15]	Finn RS, Aleshin A, Slamon DJ. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Research. 2016 Feb 9; 18(1): 17.
[16]	O’Sullivan CC. Overcoming endocrine resistance in hormone-receptor positive advanced breast cancer-the emerging role of CDK4/6 inhibitors. International journal of cancer and clinical research. 2015; 2(4).
[17]	Mangini NS, Wesolowski R, Ramaswamy B, Lustberg MB, Berger MJ. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor–Positive Advanced Breast Cancer. Annals of Pharmacotherapy. 2015 Nov; 49(11): 1252-60.
[18]	Schott S, Schneeweiss A, Reinhardt J, Bruckner T, Domschke C, Sohn C, Eichbaum MH. Acceptance of oral chemotherapy in breast cancer patients-a survey study. BMC cancer. 2011 Apr 12; 11(1): 129.
[19]	Findlay M, Von Minckwitz G, Wardley A. Effective oral chemotherapy for breast cancer: pill ars of strength. Annals of Oncology. 2007 Nov 15; 19(2): 212-22.